Telix Pharmaceuticals appoints Mr. Richard Valeix in EMEA zone
MELBOURNE, Australia and HERSTAL, Belgium, May 2, 2021 (GLOBE NEWSWIRE) – Telix Pharmaceuticals Limited (ASX: TLX, Telix, the company) announces today that Mr. Richard Valeix has joined the Telix management team as President, Europe, Middle East and Africa (EMEA).
Richard joins Telix with over 20 years of experience in the pharmaceutical industry, including radiopharmaceuticals, gained in senior management positions in a wide range of therapeutic product areas. Before joining Telix, Richard worked at Advanced Accelerator Applications (AAA), a Novartis company where he served for seven years as Managing Director for France, Switzerland, Belgium, the Netherlands and Luxembourg, and global director of marketing and sales. Earlier in his career, Richard held senior sales, marketing and strategy positions at Ipsen and Roche, where he gained extensive experience in European market access, reimbursement, regulatory affairs and regulatory affairs. planning the commercial launch of leading products.
Richard holds a Pharmacist’s degree from the Pharmaceutical University of Marseille (France), a Master in Management from ESC Business School Marseille, and followed the International Marketing Program of INSEAD, Paris ( France).
Telix CEO Dr Christian Behrenbruch said: “I am delighted to welcome Richard to the Telix management team. Richard brings to the company a wealth of experience and a proven track record of successfully launching radiopharmaceuticals that change practice in the diverse market in the EMEA region. Richard’s broad business skills and previous experience are uniquely aligned with preparations for Telix’s European commercial launch for the prostate cancer imaging product Illuccix®and the broader product pipeline that will follow. “
Mr. Valeix added: “Telix has made rapid progress in a short period of time to develop an exciting portfolio of radiopharmaceutical actives that address significant unmet needs in oncology. Having joined Telix, I look forward to working with the team to deliver on the promise of nuclear medicine and ultimately improve outcomes for cancer patients. “
About Telix Pharmaceuticals Limited
Telix is a clinical-stage biopharmaceutical company focused on the development of diagnostics and therapeutics using Targeted Molecular Radiation (TM). Telix is headquartered in Melbourne, Australia, and international operations in Belgium, Japan and the United States. Telix is developing a portfolio of clinical stage products that address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX). For more information, visit www.telixpharma.com and follow Telix on Twitter @TelixPharma and LinkedIn.
Telix’s main research product, Illuccix® (TLX591-CDx) for prostate cancer imaging, has been accepted for filing by the US FDA,1 and is undergoing priority review by the Australian Therapeutic Goods Administration (TGA).2 Telix is also advancing Illuccix marketing authorization applications® in the European Union3 and Canada.4 None of the Telix products have received marketing authorization in any jurisdiction.
1 ASX Disclosure 11/24/20.
2 ASX Disclosure 04/14/21.
3 ASX Disclosure 5/1/20.
4 ASX Disclosure 12/16/20.